Stocks · News reference

Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

Sep 15, 2026, 1:38 PMBenzinga Newsdesk

Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 15, 2026, 1:38 PM
Checked: Sep 15, 2026, 1:38 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 5, 2026, 5:24 PMBenzinga Newsdesk
Benitec Biopharma shares are trading higher after the company announced that BB-301 pivotal trial remains on track to begin in mid-2027 and the final pivotal study design is expected to be confirmed in Q1 2027.
BNTC
SEC EDGAROct 5, 2026, 12:08 PMSEC EDGAR
8-K filing — Benitec Biopharma Inc. (BNTC)
Filed: 2026-10-05 AccNo: 0001193125-26-413177 Size: 192 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
BNTC
BenzingaOct 5, 2026, 12:06 PMBenzinga Newsdesk
Benitec Biopharma Says FDA Requested More Data On Single-Arm Pivotal Study Of BB-301 In Oculopharyngeal Muscular Dystrophy; Expects Final Design In Q1 2027
BNTC